[Corrective effect of cyclooxygenase inhibitor on functional status of mononuclear cells expressing Toll-like receptors]
- PMID: 20218345
[Corrective effect of cyclooxygenase inhibitor on functional status of mononuclear cells expressing Toll-like receptors]
Abstract
Aim: To study the influence of the COX inhibitor--lornoxicam (LX)--on Toll-like receptor (TLR)-mediated production of proinflammatory and anti-inflammatory cytokines by peripheral blood mononuclear cells (PBMC) from healthy subjects and patients with acute pancreatitis (AP) in vitro.
Materials and methods: Cytokine production by PBMC of healthy donors was stimulated by TLR1/2 ligand peptidoglycan (PG) and TLR4 ligand lypopolysaccharide (LPS) in presence of LX. Levels of cyotokines (IL-1beta, IL-6, IL-8, IL-10, IL-12, and TNFalpha) were measured by ELISA. Group of patients with acute pancreatitis of toxic etiology included 11 subjects: patients from main group received combined therapy supplemented with NSAID from the oxicam class--LX; patients who received only standard basic treatment formed comparison group.
Results: It was found that in vitro LX inhibits production of both proinflammatory and anti-inflammatory cytokines by PBMC of healthy subjects mediated by ligands of TLR1/2 and TLR4. Maximal inhibitory effect of LX was observed when cytokine production was induced through TLR1/2. Patients with AP demonstrated increased production of TNFalpha induced by TLR1/2 and TLR4 ligands.
Conclusion: LX inhibits TLR-mediated production of both proinflammatory (IL-1, IL-6, IL-8, IL-12, TNFalpha) and anti-inflammatory (IL-10) cytokinesby PBMC of healthy subjects in vitro. Treatment with LX in patients with AP results in diminished effector function of TLR1/2 and TLR4 already during 1st day of the illness and normalization of these indices by 6th day.
Similar articles
-
The effect of lornoxicam on TLR2 and TLR4 messenger RNA expression and tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion in patients with systemic complications of acute pancreatitis.Pancreas. 2015 Jul;44(5):824-30. doi: 10.1097/MPA.0000000000000344. Pancreas. 2015. PMID: 25872171 Clinical Trial.
-
[The systemic inflammatory response syndrome correction in acute destructive pancreatitis].Eksp Klin Gastroenterol. 2011;(7):18-23. Eksp Klin Gastroenterol. 2011. PMID: 22363994 Clinical Trial. Russian.
-
[Antimediatory therapy in the complex treatment of acute destructive pancreatitis].Khirurgiia (Mosk). 2010;(3):54-61. Khirurgiia (Mosk). 2010. PMID: 20524238 Russian. No abstract available.
-
[Role of innate immunity receptors in development of acute myocardial infarction].Zh Mikrobiol Epidemiol Immunobiol. 2008 Jul-Aug;(4):64-8. Zh Mikrobiol Epidemiol Immunobiol. 2008. PMID: 18819410 Russian.
-
The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro.Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474. Inflamm Res. 1999. PMID: 10450786